Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Authors	Gail J Roboz, Karen Yee, Amit Verma, Gautam Borthakur, Adolfo de la Fuente Burguera, Guillermo Sanz, Helai P Mohammad, Ryan G Kruger, Natalie O Karpinich, Geraldine Ferron-Brady, Andre Acusta, Heather Del Buono, Therese Collingwood, Marc Ballas, Arindam Dhar, Andrew H Wei
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 2 Pg. 463-467 (02 2022) ISSN: 1029-2403 [Electronic] United States
PMID	34927529 (Publication Type: Clinical Trial, Phase I, Letter, Research Support, Non-U.S. Gov't)
Chemical References	Benzoates Cyclopropanes GSK2879552 Lysine
Topics	Benzoates Cyclopropanes Humans Leukemia, Myeloid, Acute (drug therapy) Lysine Myelodysplastic Syndromes (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!